Diamicron

(Gliclazide)

ApprovedSmall molecule

Gliclazide is used to help control blood sugar levels in people with type 2 diabetes by stimulating the pancreas to produce more insulin.[2] Diamicron is currently approved and in use across 8 indications[4].[1]

Diamicron is one of 252 small molecule programs targeting Endothelial Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

251

Competitors

Pipeline

Status by Indication[4][1]

Indication

Endothelial DysfunctionActive, not recruiting

Thrombotic DiseaseActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Type 2 Diabetes MellitusApproved

Diabetes MellitusUnknown

PsoriasisActive, not recruiting

EpilepsyActive, not recruiting

Type 2 DiabetesActive, not recruiting

Endothelial DysfunctionPhase 3

Active, not recruiting

Thrombotic DiseasePhase 2

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Type 2 Diabetes MellitusApproved

Approved

Diabetes MellitusPreclinical

Unknown

PsoriasisPhase 2

Active, not recruiting

EpilepsyPhase 1

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Diamicron

Merck & Co.

Approved

7 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Diabetes

NCT02879409

Clinical

Trials by Indication[1]

Type 2 Diabetes7 trials

Variation in Sulphonylurea Response in Type 2 Diabetes

Terminated·NNHS Tayside·Phase 4·NCT00738088·14 enrolled

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT01022762·440 enrolled

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Completed· Novartis logo

Novartis·Phase 3·NCT00102466·1,007 enrolled

Show 4 more trials

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

Completed· Novartis logo

Novartis·Phase 4·NCT01758380·557 enrolled

Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.

Not yet recruiting·YYan Bi·N/A·NCT06222476·106 enrolled

Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes

Completed· Novartis logo

Novartis·Phase 3·NCT00102388·1,092 enrolled

Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT02610088·32 enrolled

T2DM2 trials

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

Completed·UUniversity of Leicester·Phase 4·NCT02694263·25 enrolled

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Unknown status·SSherief Abd-Elsalam·Phase 3·NCT03313661·60 enrolled

Interaction2 trials

Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers

Completed·UUniversity of Sarajevo·Phase 1·NCT04198948·15 enrolled

Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03467945·40 enrolled

Tics2 trials

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Completed·BBial - Portela C S.A.·Phase 1·NCT02777671·20 enrolled

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

Withdrawn·UUniversity of Glasgow·Phase 4·NCT00225342·60 enrolled

Psoriasis1 trial

Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.

Completed·UUniversity College Dublin·Phase 2·NCT01991197·20 enrolled

9 more indications

Cognitive impairment1 trial

Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT06085703·24 enrolled

Safety and Efficacy1 trial

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01709305·5,570 enrolled

ESS1 trial

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Completed·KKhoo Teck Puat Hospital·Phase 4·NCT02201602·8 enrolled

Endothelial Dysfunction1 trial

Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin

Terminated·HHospices Civils de Lyon·Phase 3·NCT00169624·30 enrolled

Type 2 Diabetes Mellitus1 trial

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01590771·498 enrolled

Diabetes1 trial

HbA1c Variability in Type II Diabetes

Active, not recruiting·WWeill Cornell Medical College in Qatar·N/A·NCT02879409·150 enrolled

Adverse Reaction1 trial

Safety Evaluation of Adverse Reactions in Diabetes

Completed·—·Phase 4·NCT02092597·42 enrolled

Type 2 Diabetic Patients1 trial

Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

Completed·SSun Yat-sen University·N/A·NCT00147836·436 enrolled

Unspecified2 trials

Study of Sulphonylurea Synergy With Incretins

Completed·UUniversity of Dundee·N/A·NCT03705195·20 enrolled

Antidiabetic Effects on Intrahepatic Fat

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT03068065·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Gliclazide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Diamicron drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Gliclazide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Gliclazide. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sulfonylurea Receptor 1, Kir6.2 Blocker[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Merck & Co.

Diamicron

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes7 trials

T2DM2 trials

Interaction2 trials

Tics2 trials

Psoriasis1 trial

Cognitive impairment1 trial

Safety and Efficacy1 trial

ESS1 trial

Endothelial Dysfunction1 trial

Type 2 Diabetes Mellitus1 trial

Diabetes1 trial

Adverse Reaction1 trial

Type 2 Diabetic Patients1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News